enEnglisch
Pembrolizumab (MK-3475, KEYNOTE-051)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (KEYNOTE-051)
Recruiting
Summary
Pembrolizumab (MK-3475) is approved for the treatment of advanced cancer in adults. This phase I/II trial investigates the safety and antitumour activity of pembrolizumab for pediatric patients with either advanced melanoma, a PD-L! positive advanced, relapsed or refractory solid tumor or other lymphoma. Pembrolizumab is administered intravenous.
Main inclusion criteria
- advanced melanoma (12 to 18 years)
- adjuvant melanoma (12 to 18 years), treatment‑naïve except for surgery, to be enrolled within 12 weeks after surgery
MSI‑ or TMB‑high histologically or cytologically confirmed advanced or metastatic solid tumor that has not responded to standard therapy (6 months to 18 years)
Sponsor
Merck Sharp Dohme Corp.